FDA Approval Expands Indication for Medtronic's Resolute DES to Treat De Novo CTO


February 26, 2019—Medtronic announced FDA approval of an expanded indication for its Resolute drug-eluting stent (DES) platform for the treatment of patients with coronary artery disease who have de novo chronic total occlusions (CTOs). The platform includes the Resolute Onyx DES and the Resolute Integrity DES.

According to Medtronic, the expanded CTO indication was supported by data from the single-center, observational PERSPECTIVE study of 183 patients with CTOs who underwent stent placement with the older-generation Resolute Integrity DES. In the study, patients with CTOs treated with the Resolute DES exhibited low rates of repeat revascularization (1.1%), cardiac death (2.2%), and minimal stent thrombosis (0.6%) at 1 year.

The newer-generation Resolute Onyx DES, which was approved in the United States in 2017, features the company's core wire technology and is available in a size matrix covering 2.0 to 5.0 mm. It can be used in complex CTO lesions in a broad range of vessel sizes, advised Medtronic.

David Kandzari, MD, is Director of Interventional Cardiology and Chief Scientific Officer at Piedmont Heart Institute in Atlanta, Georgia, and Principal Investigator in the PERSPECTIVE study.

In Medtronic's announcement, Dr. Kandzari commented, "Revascularization of CTO presents physicians with many challenges—both regarding procedural technique and tools—given the patient and disease complexity. In part because of these challenges, CTO remains undertreated in interventional cardiology. The newest-generation, thin-strut Resolute Onyx DES, in particular, is well-suited to address the procedural challenges of deliverability and conformability, with now-demonstrated excellent early and late safety and efficacy."


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.